Tags

Type your tag names separated by a space and hit enter

Non-alcoholic fatty liver disease in type 2 diabetes: pathogenesis and treatment options.
Curr Vasc Pharmacol 2012; 10(2):162-72CV

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a common disorder and its prevalence is expected to increase due to the rising incidence of type 2 diabetes mellitus (T2DM) and obesity. NAFLD is associated with increased mortality rates and cardiovascular disease is the leading cause of death in these patients. The pathogenesis of NAFLD is not completely elucidated but insulin resistance and oxidative stress appear to play a major role. NAFLD is more prevalent and more severe in patients with T2DM. A multitude of pharmacological agents have been evaluated in NAFLD but most studies were small, short-term and yielded unsatisfactory results in terms of efficacy. Patients with T2DM and NAFLD appear to be even less responsive to the evaluated agents. Thus, the optimal management strategy for NAFLD remains unclear. On the other hand, preliminary data suggest that lifestyle intervention can reduce the incidence of NAFLD in overweight or obese patients with T2DM. Accordingly, prevention of obesity and T2DM is of paramount importance for the reduction of the prevalence of NAFLD and of its associated cardiovascular and liver-related complications.

Authors+Show Affiliations

First Propedeutic Department of Internal Medicine, AHEPA Hospital, Thessaloniki, Greece. ktziomalos@yahoo.comNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

22239625

Citation

Tziomalos, Konstantinos, et al. "Non-alcoholic Fatty Liver Disease in Type 2 Diabetes: Pathogenesis and Treatment Options." Current Vascular Pharmacology, vol. 10, no. 2, 2012, pp. 162-72.
Tziomalos K, Athyros VG, Karagiannis A. Non-alcoholic fatty liver disease in type 2 diabetes: pathogenesis and treatment options. Curr Vasc Pharmacol. 2012;10(2):162-72.
Tziomalos, K., Athyros, V. G., & Karagiannis, A. (2012). Non-alcoholic fatty liver disease in type 2 diabetes: pathogenesis and treatment options. Current Vascular Pharmacology, 10(2), pp. 162-72.
Tziomalos K, Athyros VG, Karagiannis A. Non-alcoholic Fatty Liver Disease in Type 2 Diabetes: Pathogenesis and Treatment Options. Curr Vasc Pharmacol. 2012;10(2):162-72. PubMed PMID: 22239625.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Non-alcoholic fatty liver disease in type 2 diabetes: pathogenesis and treatment options. AU - Tziomalos,Konstantinos, AU - Athyros,Vassilios G, AU - Karagiannis,Asterios, PY - 2011/08/15/received PY - 2011/08/16/revised PY - 2011/10/27/accepted PY - 2012/1/14/entrez PY - 2012/1/14/pubmed PY - 2012/6/14/medline SP - 162 EP - 72 JF - Current vascular pharmacology JO - Curr Vasc Pharmacol VL - 10 IS - 2 N2 - Non-alcoholic fatty liver disease (NAFLD) is a common disorder and its prevalence is expected to increase due to the rising incidence of type 2 diabetes mellitus (T2DM) and obesity. NAFLD is associated with increased mortality rates and cardiovascular disease is the leading cause of death in these patients. The pathogenesis of NAFLD is not completely elucidated but insulin resistance and oxidative stress appear to play a major role. NAFLD is more prevalent and more severe in patients with T2DM. A multitude of pharmacological agents have been evaluated in NAFLD but most studies were small, short-term and yielded unsatisfactory results in terms of efficacy. Patients with T2DM and NAFLD appear to be even less responsive to the evaluated agents. Thus, the optimal management strategy for NAFLD remains unclear. On the other hand, preliminary data suggest that lifestyle intervention can reduce the incidence of NAFLD in overweight or obese patients with T2DM. Accordingly, prevention of obesity and T2DM is of paramount importance for the reduction of the prevalence of NAFLD and of its associated cardiovascular and liver-related complications. SN - 1875-6212 UR - https://www.unboundmedicine.com/medline/citation/22239625/Non_alcoholic_fatty_liver_disease_in_type_2_diabetes:_pathogenesis_and_treatment_options_ L2 - http://www.eurekaselect.com/89576/article DB - PRIME DP - Unbound Medicine ER -